Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
In recent years, highly effective target drugs – inhibitors of interleukin 17A (iIL17A) – monoclonal antibodies, – have been widely used to treat patients with psoriatic arthritis (PsA). The efficacy of iIL-17A in psoriasis, PsA, and axial spondyloarthritis has been proven in large multicenter rando...
Saved in:
| Main Author: | Т. V. Korotaeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-04-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1130 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ixekizumab in the treatment of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2024-12-01) -
Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
by: T. V. Korotaeva, et al.
Published: (2020-11-01) -
Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01) -
Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study
by: Arfenya E. Karamova, et al.
Published: (2025-06-01) -
PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva
Published: (2016-07-01)